<DOC>
	<DOCNO>NCT00001053</DOCNO>
	<brief_summary>To evaluate safety immunogenicity HIV p17/p24 : Ty-VLP ( virus-like particle ) vaccine uninfected volunteer . Specifically , determine whether vaccine formulate without alum induces CD8+ cytotoxic T lymphocytes ( CTLs ) may cross-reactive multiple HIV-1 stain . Also , determine whether boost vaccine orally rectally help induce mucosal antibody response . Induction CD8+ CTL activity consider critical property candidate vaccine . Additionally , since majority HIV-1 infection occur inoculation mucosal surface , desirable induce mucosal immunity well systemic immunity . The HIV p17/p24 : Ty-VLP vaccine may potentially induce CTL mucosal antibody responses HIV-1 .</brief_summary>
	<brief_title>A Phase I Safety Immunogenicity Study HIV p17/p24 : Ty-VLP HIV-1 Seronegative Subjects</brief_title>
	<detailed_description>Induction CD8+ CTL activity consider critical property candidate vaccine . Additionally , since majority HIV-1 infection occur inoculation mucosal surface , desirable induce mucosal immunity well systemic immunity . The HIV p17/p24 : Ty-VLP vaccine may potentially induce CTL mucosal antibody responses HIV-1 . Volunteers receive HIV p17/p24 : Ty-VLP vaccine placebo IM injection ( without alum adjuvant ) month 0 , 2 , 6 , either mouth rectal enema month 10 11 . Volunteers receive oral vaccine boost receive concurrent omeprazole decrease stomach acid .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Omeprazole give concurrently patient receive oral vaccine dose . Volunteers must : HIV1 negativity . Normal history physical exam . Lower risk HIV infection . CD4 count &gt; = 400 cells/mm3 . Normal urine dipstick esterase nitrite . NOTE : No 10 percent volunteer may age 50 . Exclusion Criteria Coexisting Condition : Volunteers follow condition exclude : Positive hepatitis B surface antigen . Medical psychiatric condition ( include recent suicidal ideation present psychosis ) preclude compliance . Occupational responsibility preclude compliance . Active syphilis ( NOTE : If serology document false positive due remote ( &gt; 6 month ) infection , subject eligible ) . Active tuberculosis ( NOTE : Subjects positive PPD normal xray show evidence TB require INH therapy eligible ) . Volunteers follow prior condition exclude : History immunodeficiency , chronic illness , malignancy , autoimmune disease , use immunosuppressive medication . History cancer unless surgically excise reasonable assurance cure . History suicide attempt past psychosis . History anaphylaxis serious adverse reaction vaccine . History serious allergic reaction require hospitalization emergent medical care . Prior Medication : Excluded : Prior HIV1 vaccine placebo HIV vaccine trial . Live attenuate vaccine within past 60 day . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclude administer least 2 week prior HIV immunization . Experimental agent within past 30 day . Prior Treatment : Excluded : Blood product immunoglobulin within past 6 month . Higher risk behavior HIV infection determine screen questionnaire , include : History injection drug use within past year . Higher intermediate risk sexual behavior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Recombinant Proteins</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Core Protein p24</keyword>
	<keyword>p24-VLP vaccine</keyword>
	<keyword>Gene Products , gag</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>